Relmada Therapeutics, Inc. (RLMD)

Relmada Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	1.34	4.09	5.4	44.44	2.5	36.28
Short-Term Investments	82.28	92.23	142.93	167.47	114.6	80.16
Cash & Cash Equivalents	83.61	96.32	148.32	211.91	117.09	116.44
Cash Growth	-36.87%	-35.06%	-30.01%	80.98%	0.56%	5100.82%
Receivables	0	0	0.51	0.09	0.17	0.24
Other Current Assets	0.75	1.19	4.04	11.3	0.82	0.26
Total Current Assets	84.37	97.51	152.87	223.3	118.07	116.94
Property, Plant & Equipment	0	0	0	0	0	0.01
Other Long-Term Assets	0.04	0.04	0.03	0.03	0.11	0.19
Total Long-Term Assets	0.04	0.04	0.03	0.03	0.11	0.2
Total Assets	84.41	97.55	152.91	223.33	118.19	117.14
Accounts Payable	5.19	3.51	5.26	11.19	8.35	0.52
Current Debt	0	0	0	0	0	0.11
Other Current Liabilities	7.17	8.69	7.21	3.87	4.26	0.82
Total Current Liabilities	12.36	12.19	12.47	15.06	12.6	1.46
Total Liabilities	12.36	12.19	12.47	15.06	12.6	1.46
Total Debt	0	0	0	0	0	0.11
Debt Growth	-	-	-	-	-	-96.25%
Retained Earnings	-582.73	-560.9	-462.11	-305.07	-179.32	-119.86
Shareholders' Equity	72.05	85.36	140.44	208.26	105.58	115.68
Net Cash / Debt	83.61	96.32	148.32	211.91	117.09	116.33
Net Cash / Debt Growth	-36.87%	-35.06%	-30.01%	80.98%	0.65%	-
Net Cash Per Share	2.77	3.20	5.01	12.07	7.51	12.59
Working Capital	72	85.31	140.4	208.24	105.47	115.48
Book Value Per Share	2.39	2.84	4.74	11.87	6.77	12.52

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).